Ignite Creation Date:
2025-12-24 @ 4:40 PM
Ignite Modification Date:
2026-01-02 @ 6:33 AM
Study NCT ID:
NCT05366166
Status:
RECRUITING
Last Update Posted:
2025-04-23
First Post:
2022-05-04
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Pembrolizumab Plus Olaparib in LA-HNSCC
Sponsor:
UNC Lineberger Comprehensive Cancer Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-09-02
Start Date Type:
ACTUAL
Primary Completion Date:
2025-10-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-10-31
Completion Date Type:
ESTIMATED
First Submit Date:
2022-05-04
First Submit QC Date:
None
Study First Post Date:
2022-05-09
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-04-21
Last Update Post Date:
2025-04-23
Last Update Post Date Type:
ACTUAL